MindBio Therapeutics Corp

MindBio Therapeutics Corp. engages in the development of psychedelic substances for mental health conditions. The company creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. The company is focused on microdosing of psychedelic medicines and is advancing its drug and technology through clinical trials. The company develops a multidisciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase I clinical trials in 80 healthy participants and has completed Phase II clinical trials in patients with Major Depressive Disorder. Underway are Phase IIB trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. The company invests in research that forms the basis for developing novel and clinically proven treatments.